

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

**ANNOUNCEMENT
INSIDE INFORMATION**

**ASCLETIS ANNOUNCES COMPLETION OF FIRST SALE OF
ITS RITONAVIR TABLETS IN ZHEJIANG PROVINCE**

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the first sale of its ritonavir tablets in Zhejiang Province has been completed.

On April 3, 2022, Ascletis’ distributor, Zhejiang Int’l Medicine Co., Ltd. (浙江英特藥業有限責任公司, “**Zhejiang Int’l**”), completed the first sale of Ascletis’ ritonavir tablets in Zhejiang Province. Zhejiang Int’l is a major company engaged in the wholesale and retail of pharmaceuticals and medical equipment in Zhejiang Province.

As a leading antiviral company in China, to date, Ascletis owns the only authorized ritonavir tablet in China, which has passed bioequivalence study. Ascletis’ ritonavir tablet was approved in September 2021 by China National Medical Products Administration (國藥准字H20213698).

Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases. *Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9)* (《**新型冠狀病毒肺炎診療方案(試行第九版)**》) released on March 15, 2022 by the National Health Commission of the People’s Republic of China includes PF-07321332/ritonavir (Paxlovid) as an antiviral therapy for Coronavirus Disease 2019 (COVID-19).

Ascletis has further expanded its ritonavir tablet production capacity to approximately 530 million tablets per year to secure the supplies. Ascletis has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in 12 European countries (Germany, France, Ireland, the United Kingdom, Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) and Hong Kong, China.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
April 4, 2022

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.